A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
eVOLVE-HNSCC
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
1 other identifier
interventional
1,145
23 countries
305
Brief Summary
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2023
Longer than P75 for phase_3
305 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2023
CompletedFirst Posted
Study publicly available on registry
November 13, 2023
CompletedStudy Start
First participant enrolled
December 14, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 18, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 12, 2030
March 16, 2026
March 1, 2026
4.3 years
November 3, 2023
March 13, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause (in the absence of progression). The analysis will include all randomized participants with PD-L1 expressing tumors.
Up to approximately 8 years
Secondary Outcomes (13)
Progression-Free Survival (PFS) in the unresected LA-HNSCC intent-to-treat (ITT) population
Up to approximately 8 years
Landmark Progression-Free Survival (PFS) Rates
Up to approximately 8 years
Overall Survival (OS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
Up to approximately 8 years
Landmark Overall Survival (OS) Rates
Up to approximately 8 years
Overall Survival (OS) in the unresected LA-HNSCC ITT population
Up to approximately 8 years
- +8 more secondary outcomes
Study Arms (2)
Study Arm
EXPERIMENTALParticipants in this arm will receive volrustomig.
Observation Arm
NO INTERVENTIONPatients in this arm will undergo observation.
Interventions
Eligibility Criteria
You may qualify if:
- Histologically or cytologically documented locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, oral cavity, or larynx with no evidence of metastatic disease (i.e. M0).
- Confirmed unresected Stage III, Stage IVA or IVB according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor, node, metastasis (TNM) staging system).
- Participants will have completed definitive concurrent chemoradiotherapy (cCRT) with curative intent prior to randomization.
You may not qualify if:
- Participants with any of the following:
- LA-HNSCC that was resected before definitive cCRT
- LA-HNSCC that was treated and is recurrent at the time of screening
- Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (305)
Research Site
Birmingham, Alabama, 35233, United States
Research Site
Phoenix, Arizona, 85028, United States
Research Site
Prescott Valley, Arizona, 86314, United States
Research Site
Springdale, Arkansas, 72762, United States
Research Site
Fountain Valley, California, 92708, United States
Research Site
Los Angeles, California, 90024, United States
Research Site
Orange, California, 92868, United States
Research Site
San Francisco, California, 94143, United States
Research Site
Santa Rosa, California, 95403, United States
Research Site
Whittier, California, 90602, United States
Research Site
Aurora, Colorado, 80045, United States
Research Site
Colorado Springs, Colorado, 80909, United States
Research Site
Lone Tree, Colorado, 80124, United States
Research Site
Washington D.C., District of Columbia, 20037, United States
Research Site
Fort Myers, Florida, 33901, United States
Research Site
Gainesville, Florida, 32610, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Palm Bay, Florida, 32909, United States
Research Site
West Palm Beach, Florida, 33401, United States
Research Site
Niles, Illinois, 60714, United States
Research Site
Des Moines, Iowa, 50309, United States
Research Site
Kansas City, Kansas, 66160, United States
Research Site
Louisville, Kentucky, 40202, United States
Research Site
Baton Rouge, Louisiana, 70817, United States
Research Site
Shreveport, Louisiana, 71101, United States
Research Site
Baltimore, Maryland, 21231, United States
Research Site
Bethesda, Maryland, 20817, United States
Research Site
Hyattsville, Maryland, 20782, United States
Research Site
Towson, Maryland, 21204, United States
Research Site
Upper Marlboro, Maryland, 20774, United States
Research Site
Boston, Massachusetts, 02215, United States
Research Site
Fairhaven, Massachusetts, 02719, United States
Research Site
Ann Arbor, Michigan, 48105, United States
Research Site
Ann Arbor, Michigan, 48109, United States
Research Site
Minneapolis, Minnesota, 55417, United States
Research Site
Columbia, Missouri, 65211, United States
Research Site
St Louis, Missouri, 63110, United States
Research Site
St Louis, Missouri, 63110, United States
Research Site
East Brunswick, New Jersey, 08816, United States
Research Site
Hackensack, New Jersey, 07601, United States
Research Site
New Brunswick, New Jersey, 08901, United States
Research Site
Albuquerque, New Mexico, 87108, United States
Research Site
New York, New York, 10065, United States
Research Site
New York, New York, 10075, United States
Research Site
Stony Brook, New York, 11794, United States
Research Site
Charlotte, North Carolina, 28204, United States
Research Site
Winston-Salem, North Carolina, 27157, United States
Research Site
Cleveland, Ohio, 44106, United States
Research Site
Portland, Oregon, 97213, United States
Research Site
Portland, Oregon, 97239, United States
Research Site
Philadelphia, Pennsylvania, 19107, United States
Research Site
Pittsburgh, Pennsylvania, 15261, United States
Research Site
York, Pennsylvania, 17403, United States
Research Site
Sioux Falls, South Dakota, 57104, United States
Research Site
Sioux Falls, South Dakota, 57105, United States
Research Site
Nashville, Tennessee, 37212, United States
Research Site
Austin, Texas, 78745, United States
Research Site
Dallas, Texas, 75251, United States
Research Site
Flower Mound, Texas, 75028, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Odessa, Texas, 79761, United States
Research Site
Tyler, Texas, 75702, United States
Research Site
Salt Lake City, Utah, 84112, United States
Research Site
West Jordan, Utah, 84088, United States
Research Site
Fairfax, Virginia, 22031, United States
Research Site
Norfolk, Virginia, 23502, United States
Research Site
Richmond, Virginia, 23230, United States
Research Site
Spokane, Washington, 99204, United States
Research Site
Tacoma, Washington, 98405, United States
Research Site
Tacoma, Washington, 98415, United States
Research Site
Graz, 8036, Austria
Research Site
Innsbruck, 6020, Austria
Research Site
Linz, 4010, Austria
Research Site
Salzburg, 5020, Austria
Research Site
Vienna, 1080, Austria
Research Site
Charleroi, 6060, Belgium
Research Site
Edegem, 2650, Belgium
Research Site
Jette, 1090, Belgium
Research Site
La Louvière, 7100, Belgium
Research Site
Namur, 5000, Belgium
Research Site
Barretos, 14784-400, Brazil
Research Site
Florianópolis, 88034-000, Brazil
Research Site
Fortaleza, 60336-045, Brazil
Research Site
Ijuí, 98700-000, Brazil
Research Site
Ipatinga, 35162-189, Brazil
Research Site
Londrina, 86015-520, Brazil
Research Site
Natal, 59075-740, Brazil
Research Site
Porto Alegre, 91350200, Brazil
Research Site
Ribeirão Preto, 14051-140, Brazil
Research Site
Rio de Janeiro, 20231-050, Brazil
Research Site
São Paulo, 01509-900, Brazil
Research Site
São Paulo, 04538-132, Brazil
Research Site
Teresina, 64049-200, Brazil
Research Site
Calgary, Alberta, T2N 5G2, Canada
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
Research Site
Kelowna, British Columbia, V1Y 5L3, Canada
Research Site
Kingston, Ontario, K7L 2V7, Canada
Research Site
London, Ontario, N6A 5W9, Canada
Research Site
Toronto, Ontario, M4N 3M5, Canada
Research Site
Chicoutimi, Quebec, G7H 5H6, Canada
Research Site
Montreal, Quebec, H2X 0C1, Canada
Research Site
Montreal, Quebec, H3T 1E2, Canada
Research Site
Montreal, Quebec, H4A 3J1, Canada
Research Site
Regina, S4T 7T1, Canada
Research Site
Beijing, 100142, China
Research Site
Beijing, 100210, China
Research Site
Bengbu, 233004, China
Research Site
Changchun, 130000, China
Research Site
Changsha, 410008, China
Research Site
Changsha, 410013, China
Research Site
Chengdu, 610000, China
Research Site
Chengdu, 610042, China
Research Site
Chengdu, 610072, China
Research Site
Chongqing, 400016, China
Research Site
Chongqing, 400030, China
Research Site
Dongwan, 523058, China
Research Site
Fuzhou, 350014, China
Research Site
Guangzhou, 510060, China
Research Site
Guangzhou, 510080, China
Research Site
Guangzhou, 510095, China
Research Site
Guangzhou, 510700, China
Research Site
Guiyang, 550002, China
Research Site
Hangzhou, 310022, China
Research Site
Harbin, 150049, China
Research Site
Hefei, 230001, China
Research Site
Huizhou, 516001, China
Research Site
Jinan, 250117, China
Research Site
Kunming, 650118, China
Research Site
Lanzhou, 730000, China
Research Site
Nanchang, 330029, China
Research Site
Nanning, 530021, China
Research Site
Shanghai, 20032, China
Research Site
Shenyang, 110004, China
Research Site
Shijiazhuang, 050000, China
Research Site
Tianjin, 300060, China
Research Site
Tianjin, 300060, China
Research Site
Ürümqi, 830000, China
Research Site
Wuhan, 430030, China
Research Site
Wuhan, 430060, China
Research Site
Wuxi, 214122, China
Research Site
Xi'an, 710061, China
Research Site
Xiamen, 361003, China
Research Site
Zhengzhou, 450008, China
Research Site
Zhuhai, 519000, China
Research Site
Avignon, 84918, France
Research Site
Bordeaux, 33075, France
Research Site
Le Mans, 72000, France
Research Site
Lyon, 69373, France
Research Site
Nice, 06100, France
Research Site
Saint-Herblain, 44805, France
Research Site
Toulouse, 31059, France
Research Site
Villejuif, 94805, France
Research Site
Berlin, 12200, Germany
Research Site
Erlangen, 91054, Germany
Research Site
Essen, 45122, Germany
Research Site
Freiburg im Breisgau, 79106, Germany
Research Site
Greifswald, 17475, Germany
Research Site
Hamburg, 20246, Germany
Research Site
Hanover, 30625, Germany
Research Site
Leipzig, 04103, Germany
Research Site
Lübeck, 23538, Germany
Research Site
München, 81675, Germany
Research Site
Rostock, 18059, Germany
Research Site
Tübingen, 72076, Germany
Research Site
Ulm, 89075, Germany
Research Site
Würzburg, 97070, Germany
Research Site
Budapest, 1062, Hungary
Research Site
Budapest, 1083, Hungary
Research Site
Budapest, 1122, Hungary
Research Site
Budapest, 1145, Hungary
Research Site
Győr, 9024, Hungary
Research Site
Gyula, 5700, Hungary
Research Site
Kecskemét, 6000, Hungary
Research Site
Miskolc, 3526, Hungary
Research Site
Nyíregyháza, 4400, Hungary
Research Site
Pécs, 7624, Hungary
Research Site
Szekszárd, 7100, Hungary
Research Site
Bengaluru, 560027, India
Research Site
Hyderabad, 500032, India
Research Site
Jaipur, 302022, India
Research Site
Kanpur, 208005, India
Research Site
Kochi, 682027, India
Research Site
Kolkata, 700099, India
Research Site
Lucknow, 226003, India
Research Site
Madurai, 625107, India
Research Site
Mohali, 160055, India
Research Site
Nashik, 422002, India
Research Site
New Delhi, 110076, India
Research Site
Thiruvananthapuram, 695011, India
Research Site
Vadodara, 391760, India
Research Site
Varanasi, 221005, India
Research Site
Aviano, 33081, Italy
Research Site
Florence, 50139, Italy
Research Site
Milan, 20133, Italy
Research Site
Modena, 41124, Italy
Research Site
Naples, 80131, Italy
Research Site
Padua, 35128, Italy
Research Site
Pavia, 27100, Italy
Research Site
Rozzano, 20089, Italy
Research Site
Bunkyō City, 113-8431, Japan
Research Site
Bunkyō City, 113-8519, Japan
Research Site
Chiba, 260-8677, Japan
Research Site
Chiba, 260-8717, Japan
Research Site
Chūōku, 104-0045, Japan
Research Site
Fukuoka, 811-1395, Japan
Research Site
Hidaka-shi, 350-1298, Japan
Research Site
Hiroshima, 734-8551, Japan
Research Site
Kashiwa, 277-8577, Japan
Research Site
Kobe, 650-0017, Japan
Research Site
Kōtoku, 135-8550, Japan
Research Site
Nagoya, 464-8681, Japan
Research Site
Nagoya, 466-8560, Japan
Research Site
Niigata, 951-8520, Japan
Research Site
Okayama, 700-8558, Japan
Research Site
Osaka, 541-8567, Japan
Research Site
Osakasayama-shi, 589-8511, Japan
Research Site
Sagamihara-shi, 252-0375, Japan
Research Site
Sapporo, 060-8638, Japan
Research Site
Sendai, 980-8574, Japan
Research Site
Shinjuku-ku, 160-0023, Japan
Research Site
Shiwa-gun, 028-3695, Japan
Research Site
Sunto-gun, 411-8777, Japan
Research Site
Yokohama, 236-0004, Japan
Research Site
Yokohama, 241-8515, Japan
Research Site
George Town, 10450, Malaysia
Research Site
Johor Bahru, 81100, Malaysia
Research Site
Kuala Lumpur, 50586, Malaysia
Research Site
Kuala Lumpur, 59100, Malaysia
Research Site
Kuala Selangor, 62250, Malaysia
Research Site
Kuching, 93586, Malaysia
Research Site
Cebu City, 6000, Philippines
Research Site
General Santos, 9500, Philippines
Research Site
Iloilo City, 5000, Philippines
Research Site
Manila, 1008, Philippines
Research Site
Pasig, 1605, Philippines
Research Site
Quezon City, 1112, Philippines
Research Site
West San Juan City, 1502, Philippines
Research Site
Bialystok, 15-027, Poland
Research Site
Bielsko-Biala, 43-300, Poland
Research Site
Bydgoszcz, 85-796, Poland
Research Site
Gliwice, 44-102, Poland
Research Site
Olsztyn, 10-228, Poland
Research Site
Piotrkow Trybunalski, 97-300, Poland
Research Site
Siedlce, 08-110, Poland
Research Site
Tomaszów Mazowiecki, 97-200, Poland
Research Site
Warsaw, 02-781, Poland
Research Site
San Juan, 00927, Puerto Rico
Research Site
Goyang-si, 410-769, South Korea
Research Site
Gyeonggi-do, 13620, South Korea
Research Site
Incheon, 21565, South Korea
Research Site
Seoul, 06351, South Korea
Research Site
Seoul, 3722, South Korea
Research Site
Seoul, 5505, South Korea
Research Site
Suwon, 16247, South Korea
Research Site
Badalona, 08916, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Barcelona, 08036, Spain
Research Site
Jaén, 23007, Spain
Research Site
Madrid, 28007, Spain
Research Site
Madrid, 28034, Spain
Research Site
Madrid, 28040, Spain
Research Site
Valencia, 46014, Spain
Research Site
Valencia, 46026, Spain
Research Site
Changhua, 500, Taiwan
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
Kaohsiung City, 833401, Taiwan
Research Site
Taichung, 404, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taipei, 10002, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taoyuan District, 333, Taiwan
Research Site
Bangkok, 10300, Thailand
Research Site
Bangkok, 10400, Thailand
Research Site
Bangkok, 10700, Thailand
Research Site
Chaing Mai, 50200, Thailand
Research Site
Hat Yai, 90110, Thailand
Research Site
Khon Kaen, 40002, Thailand
Research Site
Lampang, 52000, Thailand
Research Site
Muang, 22000, Thailand
Research Site
Mueang, 20000, Thailand
Research Site
Ankara, 06230, Turkey (Türkiye)
Research Site
Ankara, 6200, Turkey (Türkiye)
Research Site
Antalya, 07059, Turkey (Türkiye)
Research Site
Cordaleo, 35575, Turkey (Türkiye)
Research Site
Eskişehir, 26040, Turkey (Türkiye)
Research Site
Istanbul, 34722, Turkey (Türkiye)
Research Site
Yenimahalle, 06170, Turkey (Türkiye)
Research Site
Aberdeen, AB25 2ZN, United Kingdom
Research Site
Cambridge, CB2 0XY, United Kingdom
Research Site
Hampshire, SO16 6YD, United Kingdom
Research Site
Leeds, LS9 7TF, United Kingdom
Research Site
London, EC1A 7BE, United Kingdom
Research Site
London, SE1 9RT, United Kingdom
Research Site
London, SW3 6JJ, United Kingdom
Research Site
Manchester, M20 4BX, United Kingdom
Research Site
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Research Site
Northwood, HA6 2RN, United Kingdom
Research Site
Sutton, SM2 5PT, United Kingdom
Research Site
Taunton, TA1 5DA, United Kingdom
Research Site
Da Nang, 550000, Vietnam
Research Site
Hanoi, 100000, Vietnam
Research Site
Hà Nội, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Huế, 530000, Vietnam
Research Site
Vinh, 460000, Vietnam
Study Officials
- STUDY CHAIR
Robert Haddad, MD
Dana Farber Cancer Institute Massachusetts, USA
- STUDY CHAIR
Lisa Licitra, MD
Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan Milan, Italy
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2023
First Posted
November 13, 2023
Study Start
December 14, 2023
Primary Completion (Estimated)
April 18, 2028
Study Completion (Estimated)
September 12, 2030
Last Updated
March 16, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure